C. Kosinski

Discipline

Education (3) Linguistique (1)

Type de document

Articles (16) Recensions (9)

Co-auteur

Date

Source

Mot-clé

Diabetes (12) Patients (11) Patients (10) Human beings (10) Treatment (9) thérapie (7) Therapeutics (7) Control (6) Non-insulin-dependent diabetes (6) Glucose (6) maladie (5) maladie (5) risque (4) Case (4) Inhibitors (4) Year (4) Weights and measures (4) Toleration (4) Risk (4) Management (4) Insulin (4) Grammar, Comparative and general--Case (4) Case (4) Blood sugar (4) poids (3) temps (durée) (3) protéine (3) besoin (3) plomb (3) dosage (3)

Documents écrit par C. Kosinski (16) | parle de C. Kosinski (0)

Effects of empagliflozin on reproductive system in men without diabetes.
C. Kosinski et al. (14 juin 2024)
Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on β-Cell Function at 1 Year After Surgery: A Systematic Review.
A. Buser et al. (23 nov. 2022)
Insulines rapides et ultrarapides : quelles indications et utilités ? [Rapid and ultrarapid insulins: when and how?]
Y. Vuignier et al. (1 juin 2022)
Cardio-Metabolic and Mental Health Outcomes Before and During the COVID-19 Pandemic in a Cohort of Women With Gestational Diabetes Mellitus in Switzerland.
D.Y. Quansah et al. (2022)
Adverse metabolic outcomes in the early and late postpartum after gestational diabetes are broader than glucose control.
C. Kosinski et al.
Exposure to alirocumab during the first trimester of pregnancy: A case report.
Y. Vuignier et al. (1 sept. 2021)
Efficacy of Ketogenic Diets on Type 2 Diabetes: a Systematic Review.
D. Tinguely et al. (27 août 2021)
Insulinothérapie basale chez les patients diabétiques de type 2 [Basal insulin therapy in patients with type 2 diabetes]
Y. Vuignier et al. (2 juin 2021)
Diabète secondaire aux nouvelles thérapies ciblées contre le cancer [New-onset diabetes and novel targeted therapies against cancer]
A. Zordan et al. (2 juin 2021)
Considérations pratiques pour l’utilisation des inhibiteurs du SGLT2 dans les maladies cardiovasculaires [Practical considerations in the use of SGLT2 inhibitors in cardiovascular diseases]
H. Lu et al. (26 mai 2021)
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.
H. Lu et al. (10 mai 2021)
Diabète et infection à COVID-19 [Diabetes and COVID-19 infection]
C. Kosinski et al. (6 mai 2020)
Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
M. Zezza et al. (23 déc. 2019)
Exercise Testing in Individuals With Diabetes, Practical Considerations for Exercise Physiologists
C. Kosinski et al. (27 sept. 2019)
Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies.
C. Kosinski et al. (19 mai 2017)
Study of Early Elevated Gas6 Plasma Level as a Predictor of Mortality in a Prospective Cohort of Patients with Sepsis.
G. Stalder et al. (2016)